Patents Assigned to RESEARCH FOUNDATION (GNF)
-
Patent number: 12377048Abstract: Processes for preparing neutral liposomes include adding a hydrophobic solution of liposome lipid bilayer precursors and a nucleic acid condenser to an aqueous composition of a nucleic acid condenser and a biologically active ingredient and then, isolating the liposomes. The liposomes are formed from noncationic lipids and encapsulate the biologically active ingredient as a core composition and entrap some of the biologically active ingredient on the exterior surface of the liposome. The liposomes have the nucleic acid condensers and/or cell penetrating peptides attached to the exterior surface of the lipid bilayer. One or more divalent cations are present in the solution with the liposome and remain in solution once the liposomes form.Type: GrantFiled: January 19, 2021Date of Patent: August 5, 2025Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Richard K. Fisher, Deidra J. H. Mountain, Oscar H. Grandas
-
Patent number: 12377087Abstract: Methods and pharmaceutical compositions for inhibiting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) and the treatment of cancer are described.Type: GrantFiled: November 13, 2020Date of Patent: August 5, 2025Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Sucheta Telang, Jason Chesney, John O. Trent
-
Patent number: 12378285Abstract: Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and/or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.Type: GrantFiled: February 10, 2023Date of Patent: August 5, 2025Assignees: FLORIDA ATLANTIC UNIVERSITY RESEARCH CORPORATION, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Predrag Cudic, Jay McLaughlin
-
Patent number: 12377069Abstract: In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.Type: GrantFiled: October 26, 2023Date of Patent: August 5, 2025Assignees: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC., THE INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE (INSTEM)Inventors: Venkatakrishna Rao Jala, Haribabu Bodduluri, Rajbir Singh, Praveen Kumar Vemula, Sandeep Chandrashekharappa, Ankita Arun Hiwale
-
Patent number: 12378274Abstract: Various embodiments relate to a method for producing a metal-organic framework (MOF) having a desired redox conductivity and including redox-active linkers, having ?-alkyl-ferrocene groups, via de novo solvothermal synthesis. Various embodiments relate to a metal-organic framework (MOF) linker comprising an ?-alkyl-ferrocene group. Various embodiments relate to a metal-organic framework (MOF), having a first plurality of redox-active linkers, each having an ?-alkyl-ferrocene group. The MOF according to various embodiments, may further have one or more redox-inactive linkers. Various embodiments relate to materials, apparatuses, and components that include the MOF according to various embodiments. For example, various embodiments relate to thin-films, bulk powders, or electrodes.Type: GrantFiled: March 21, 2024Date of Patent: August 5, 2025Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Fernando Javier Uribe-Romo, Gavin Pour, David Fairchild, Joaquin Rodriguez Lopez
-
Patent number: 12370183Abstract: Disclosed are methods of treating malaria with tetrahydrobenzonaphtyridine carboxanilide (TBN) derivatives and related pyrrolinones and hydrolysis products thereof. These compounds are active against Plasmodium falciparum strains that are resistant to multiple drugs currently on the market. The present invention further relates to novel compounds and pharmaceutical compositions comprising such compounds.Type: GrantFiled: February 16, 2021Date of Patent: July 29, 2025Assignees: Rutgers, The State University of New Jersey, UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Spencer Knapp, Robert D. Barrows, R. Kiplin Guy, Jared Hammill, Christopher Davis
-
Patent number: 12374924Abstract: Various examples are provided for power amplifiers for coil array systems, which include load-independent Class E power amplifiers. In one example, a wireless charging system includes a three-dimensional (3D) coil array; and control circuitry configured to adjust a magnetic field generated by the 3D coil array, the control circuitry comprising a switching structure coupled to transmitting (TX) coils of the 3D coil array via independent matching networks. The independent matching networks can be LCL-? matching networks.Type: GrantFiled: June 18, 2024Date of Patent: July 29, 2025Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, MEDIATEK SINGAPORE LTDInventors: Jenshan Lin, Ron-Chi Kuo, Hasnain Akram
-
Publication number: 20250237655Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry.Type: ApplicationFiled: August 5, 2024Publication date: July 24, 2025Applicants: ASPIRA WOMEN'S HEALTH INC., THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: ERIC THOMAS FUNG, FREDERICK RAND UELAND, J.R. VAN NAGELL, PAUL DUANE DEPRIEST, ANDRE THOMAS BARON
-
Patent number: 12365821Abstract: The present application relates to polyurethane polymers produced by polymerizing a reactant mixture comprising triglycerides of Physaria fendleri, one or more polyisocyanates, and one or more polyols, wherein the triglycerides of Physaria fendleri have a hydroxyl value ranging from 90 milligrams of potassium hydroxide per gram of the triglycerides of Physaria fendleri to 250 milligrams of potassium hydroxide per gram of the triglycerides of Physaria fendleri. The present application also relates to polyester polymers produced by polymerizing a reactant mixture comprising triglycerides of Euphorbia lagascae, and one or more dicarboxylic acids. Also disclosed are the methods of formation of the polyurethane and polyester polymers, and their use as adhesives.Type: GrantFiled: April 17, 2024Date of Patent: July 22, 2025Assignee: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Greg Curtzwiler, Keith Vorst, Alexandra Ivey, Sharan Raman
-
Patent number: 12365912Abstract: The disclosure relates to a plant that is tolerant or resistant to species of Ca. liberibacter. Specifically exemplified are citrus and solanaceous plants. Provided by the disclosure is a modified citrus or solanaceous plant that is resistant or tolerant to Sec-dependent effectors secreted by bacteria. Also provided by the disclosure are methods of modifying a plant genome plant to provide tolerance or resistance to species of Ca. liberibacter. Still further provided by the disclosure are methods conferring a population of plants with tolerance or resistance to species of Ca. liberibacter and screening that population for the plants that are tolerant or resistant to species of Ca. liberibacter.Type: GrantFiled: December 28, 2022Date of Patent: July 22, 2025Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventor: Nian Wang
-
Patent number: 12365900Abstract: Provided herein are methods, compositions and systems comprising synthetic nucleic acid molecules that enable inducible or conditional pri-miRNA processing, preferably in mammalian cells in vivo. Provided herein are synthetic nucleic acid molecules referred to as Orthogonal RNA Interference induced by Trigger RNA (ORIENTR) that switches between an inactive form and an active form upon interaction with one or more specific RNA-trigger molecules, which can be e.g., a synthetic RNA-trigger, or a disease-specific RNA signals, such as disease-specific mRNA, miRNA, or other cellular RNA products with sequences that characterize a disease state of a cell. The interaction between the RNA-trigger molecules and the ORIENTR is preferably mediated by hybridization, which exposes, facilitates the formation, and/or allows the formation of a correctly folded pri-miRNA scaffold substrate that can be processed by proteins of the RNAi pathway (such as Dicer), leading to RNAi-mediated repression of a target gene.Type: GrantFiled: December 21, 2023Date of Patent: July 22, 2025Assignees: TRUSTEES OF BOSTON UNIVERSITY, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Alexander Arthur Green, Yu Zhou, Peike Sheng, Mingyi Xie
-
Patent number: 12368188Abstract: An alkaline battery comprises an anode, a cathode, a separator disposed between the anode and the cathode, and an electrolyte in fluid communication with the anode, the cathode, and the separator. The separator comprises at least one ion selective layer that can include at least one of graphene, graphene oxide, reduced graphene oxide, functionalized graphene, or combinations thereof. This can allow the ion selective layer to be configured to selectively block zincate ions.Type: GrantFiled: August 30, 2018Date of Patent: July 22, 2025Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: Jinchao Huang, Gautam G. Yadav, Michael Nyce, Sanjoy Banerjee
-
Patent number: 12364182Abstract: The present invention is a system and method for agricultural management-zone delineation to be done over broad geographic extents without overly-localized field-specific data. The instant innovation guides precision agricultural sampling and management by delineating enhanced management zones based upon remote sensing and artificial intelligence and combining the two with data derived from an existing countrywide soil survey database. In an embodiment, the instant innovation uses artificial intelligence from multiple sources to provide granular zone detail. Output of the present innovation can be aggregated to produce management zone sizes that have a level of uncertainty compatible with the needs of the customer-fanner and implementable given the capabilities of available equipment.Type: GrantFiled: July 19, 2023Date of Patent: July 22, 2025Assignees: SOILMETRIX, INC., IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC., NORTH CAROLINA STATE UNIVERSITYInventors: Jeffrey G. White, Bradley A. Miller, Julianne Bielski
-
Patent number: 12366705Abstract: There is set forth herein a method including building a first photonics structure using, wherein the building the first photonics structure includes fabricating one or more photonics device.Type: GrantFiled: January 9, 2023Date of Patent: July 22, 2025Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERISTY OF NEWYORKInventors: William Charles, Douglas Coolbaugh, Douglas La Tulipe, Gerald L. Leake, Jr.
-
Publication number: 20250230502Abstract: An Interferon Gamma Inducible Protein 16 (IFI16) mutant gene and its use as a marker for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease is described. As a result of performing genomic analysis on NAFLD and NASH patient groups, it was confirmed that the frequency of IFI16 single-nucleotide variants (SNVs) including rs2276404, rs73021847, rs7532207, and rs6940 was increased, and the expression of the IFI16 mutant gene was increased depending on the disease stage of liver disease. The IFI16 SNV was highly expressed in infiltrating macrophages, playing a role in macrophage-induced inflammatory processes, and the IFI16 variant bound more strongly to dsDNA than wild-type IFI16, exacerbating the impaired mitochondrial DNA-sensing response signaling of the IFI16-PYCARD-CASP1 pathway. Thus, the IFI16 mutant gene may be used for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease.Type: ApplicationFiled: March 30, 2023Publication date: July 17, 2025Applicants: NATIONAL CANCER CENTER, AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION, ON HOSPITALInventors: Yeon Su LEE, Gaeul PARK, Yong Sun LEE, Hyun Goo WOO, Do Yoon KIM, Rho Hyun SEONG, Yang Hyun BAEK, Sang Young HAN
-
Publication number: 20250230201Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.Type: ApplicationFiled: January 15, 2025Publication date: July 17, 2025Applicant: THE UAB RESEARCH FOUNDATIONInventors: Michael Niederweis, Mikhail Pavlenok
-
Patent number: 12357600Abstract: Formulations comprising particular free amino acids useful for promoting hydration and/or intestinal barrier function in a subject in need thereof are described herein. Such formulations and methods using same are useful for promoting hydration and/or intestinal barrier function in a subject in need thereof. Such subjects may be healthy, but in need of a formulation that promotes rapid hydration (e.g., within 15-90 minutes post-administration) or promotes intestinal barrier function; or such subjects may be afflicted by a disorder or disease associated with dehydration or impaired intestinal barrier function, respectively.Type: GrantFiled: December 30, 2022Date of Patent: July 15, 2025Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, AMILYFE, LLC.Inventors: Sadasivan Vidyasagar, Astrid Grosche, Xiaodong Xu, Shanshan Lin, Samuel Cheuvront, Robert Kenefick, Stephen Gatto
-
Patent number: 12360262Abstract: A multiplexing scheme for both energy and timing information is provided for a particle detection system having an optical sensor array with multiple optical sensors. Each optical sensor is associated with multiple scintillator modules. The system has a segmented prismatoid light guide comprising multiple prismatoid segments. Each segment is associated with multiple optical sensors, where the optical sensors are adjacent. One end each scintillator module is in contact with its associated optical sensor and the other is in contact with its associated segment. Multiple optical sensors may be connected to an energy readout channel, respectively, such that optical sensors associated with the same segments are not connected to the same energy readout channel. Each energy readout channel has at least two timestamps associated therewith.Type: GrantFiled: October 7, 2021Date of Patent: July 15, 2025Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Andrew Labella, Amirhossein Goldan, Eric Petersen, Wei Zhao
-
Patent number: 12357080Abstract: A system and method for monitoring and analyzing activities of a user operating an electric tooth brush having an electric motor. The magnetic field induced by motions of the electric motor can be detected by a sensor array to generate signals. The signals are processed to determine a position of the brush head and a roll angle of the brush head. Based on the position and roll angle of the brush head, the surface of the teeth of the user, which is being brushed by the brush head, can be determined. This operation can be repeated to determine whether all the surfaces of the teeth have been brushed.Type: GrantFiled: June 19, 2020Date of Patent: July 15, 2025Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventor: Shan Lin
-
Patent number: 12350328Abstract: The present invention provides compositions and methods related to equine live-attenuated influenza vaccines. In one aspect, the invention relates to a composition comprising a multivalent equine live-attenuated influenza vaccine comprising a first live-attenuated influenza virus expressing one or more antigens of a clade 1 H3N8 equine influenza virus; and a second live-attenuated influenza virus expressing one or more antigens of a clade 2 H3N8 equine influenza virus, wherein the second live-attenuated influenza virus expresses HA, NA, or a combination thereof of A/equine/Lancashire/1/2016 H3N8.Type: GrantFiled: February 27, 2020Date of Patent: July 8, 2025Assignees: University of Rochester, UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, ZOETIS SERVICES LLCInventors: Luis Martinez-Sobrido, Thomas Chambers, Kendall Wayne King